Yanhong Deng

25PUBLICATIONS
137CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyMolecular targetsCancer geneticsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Sep 24, 2026
First-Line Retlirafusp Alfa Plus Chemotherapy for Human Epidermal Growth Factor Receptor 2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Double-Blind, Phase III Study (RELIGHT).

|Aug 24, 2026
EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer From a Phase Ib/II, Open-Label, Multicenter Study.

|May 22, 2026
PTEN deficiency impairs MHC-I-mediated tumour immunity via NRF2-dependent autophagy in microsatellite stable colorectal cancer.

|Mar 04, 2026
Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial.

Tianshu Liu, Suxia Luo, Xianglin Yuan

|Sep 24, 2025
Glycolysis-Driven Immune Evasion in Microsatellite Instability-High Colorectal Cancer: An Integrated Single-Cell and Spatial Transcriptomics Study.

Chenchen Li, Peicong Cai, Hengda Zeng

|Jun 30, 2025
A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors.

Geoffrey Ku, Lin Shen, Farshid Dayyani

Pageof 5

Frequent Collaborators

8 joint publications

Jianwei Zhang

6 joint publications

Lishuo Shi

5 joint publications

Huabin Hu

4 joint publications

Jianxia Li